Acadia Pharmaceuticals, Inc. (ACAD) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.47 -0.58%
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
IEP, XPRO, GEF, More
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
IEP, XPRO, GEF, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADTRAN, Inc. (ADTN) Tops Q3 EPS by 5c; offers guidance
- MFA Financial (MFA) Reiterated at Market Outperform by Citizens - 'One of the Best Deep-Value Stories'
- Viper Energy (VNOM) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
